¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö
  • minimal change disease
    ¹Ì¼¼º¯È­º´
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal identifiable odor
    ÃÖ¼ÒÀνij¿»õ, ÃÖ¼ÒºÐÇØÃë°¢
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal visible angle
    Ãּҽð¢
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • thermal enhancement ratio
    ¿Â¿­Áõ°¨ºñ
  • minimal visible angle
    Ãּҽð¢
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³»³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö, ¹Ì¼Ò³ú±â´ÉÀå¾Ö
  • minimal change disease
    ÃÖ¼Òº¯È­ÄáÆÏº´Áõ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxygen enhancement ratio (OER)
    »ê¼ÒÁõ°­ºñ
  • oxygen enhancement ratio =OER
    »ê¼ÒÈ¿°úÁõ°­·ü(¡­üùÍýñòË­ëÒ).
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­(åÕпý­ñòË­)
  • posterior echo enhancement
    ÈÄ¹æ ¿¡ÄÚ Áõ°­, ÈÄ¹æ ¸Þ¾Æ¸®Áõ°­
  • posterior echo enhancement
    ÈĹæ (ý­Û°) ¿¡ÄÚ Áõ°­ (ñòË­), ÈĹæ (ý­Û°) ¸Þ¾Æ¸® ?
  • proton relaxation enhancement
    ¾çÀÚ ÀÌ¿Ï Áõ°­
  • rapid acquisition with relaxation enhancement (RARE)
    ±Þ¼Ó ȹµæ ÀÌ¿Ï Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • ring enhancement
    ȯ»ó Á¶¿µÁõ°­
  • thermal enhancement ratio, TER
    ¿Â¿­Áõ°¨ºñ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • posterior echo enhancement
    ÈĹ濡ÄÚÁõ°­, ÈĹæ¸Þ¾Æ¸®Áõ°­
  • proton relaxation enhancement
    ¾çÀÚÀÌ¿ÏÁõ°­
  • rapid acquisition with relaxation enhancement [=RARE]
    ÀÌ¿ÏÁõ°­±Þ¼Óȹµæ
  • rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • ring enhancement
    ȯ»óÁ¶¿µÁõ°­
  • sonic enhancement
    À½ÆÄÁõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OER Oxygen Enhancement Ratio
ADE acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest...
DEPT distortionless enhancement by polarization transfer
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
FRE Fischer rat embryo; flow-related enhancement
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MET Motivational Enhancement Therapy
NOESY Nuclear Over-hauser enhancement spectroscopy
NOE Nuclear Overhauser Enhancement
OER Oxygen Enhancement Ratio
RARE Rapid Acquisition with Relaxation Enhancement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • ring enhancement
    ȯ»ó Á¶¿µ Áõ°­
  • sonic enhancement
    À½ÆÄ Áõ°­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
minimal anaesthetic concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal brain dysfunction An inability to control behaviour due to difficulty in processing neural stimuli.
(12 Dec 1998)
minimal-change disease <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
minimal-change nephrotic syndrome <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á